In the last trading session, 1.51 million Sangamo Therapeutics Inc (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.23. With the company’s per share price at $0.35 changed hands at $0.03 or 9.92% during last session, the market valuation stood at $72.63M. SGMO’s last price was a discount, traded about -377.14% off its 52-week high of $1.67. The share price had its 52-week low at $0.29, which suggests the last value was 17.14% up since then. When we look at Sangamo Therapeutics Inc’s average trading volume, we note the 3-month average coming to 2.22 million.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Instantly SGMO was in green as seen at the end of in last trading. With action 6.06%, the performance over the past five days has been green. The jump to weekly highs of 0.3579 added 9.92% to the stock’s daily price. The company’s shares are showing year-to-date downside of -35.58%, with the 5-day performance at 6.06% in the green. However, in the 30-day time frame, Sangamo Therapeutics Inc (NASDAQ:SGMO) is -40.85% down.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Data shows that the Sangamo Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -22.91% over the past 6 months, a 6.78% in annual growth rate that is considerably lower than the industry average of 15.50%. Year-over-year growth is forecast to reach -76.70% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 8.26M. 5 analysts are of the opinion that Sangamo Therapeutics Inc’s revenue for the current quarter will be 8.72M. The company’s revenue for the corresponding quarters a year ago was 14.83M and 10.4M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -44.30%. The estimates for the next quarter sales put growth at -16.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.96%. The 2024 estimates are for Sangamo Therapeutics Inc earnings to increase by 64.58%.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.73% of Sangamo Therapeutics Inc shares while 50.82% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 55.08% . There are 50.82% institutions holding the Sangamo Therapeutics Inc stock share, with Wasatch Advisors LP the top institutional holder. As of Mar 31, 2024 , the company held 9.70% of the shares, roughly 20.13 SGMO shares worth $7.05 million.
Armistice Capital, LLC holds the second largest percentage of outstanding shares, with 8.17% or 16.96 shares worth $5.94 million as of Mar 31, 2024 .
Among Mutual Funds, the top two as of Mar 31, 2024 were Wasatch Ultra Growth Fund and Wasatch Microcap Fund . With 11.82 shares estimated at $4.14 million under it, the former controlled 5.69% of total outstanding shares. On the other hand, Wasatch Microcap Fund held about 2.56% of the shares, roughly 5.32 shares worth around $1.86 million.
